D. Bellgrau

发表

Promiscuous activation and cell cycle entry in T cells from autoimmune animals.

J. K. Moore, D. Bellgrau, 1999, Transplantation proceedings.

Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines.

D. Bellgrau, Zhimin Guo, T. King, 2016, Methods in molecular biology.

A T‐Cell Functional Phenotype Common among Autoimmune‐Prone Rodent Strains

D. Bellgrau, J. Lang, Julie A. Lang, 2002, Scandinavian journal of immunology.

A role for CD95 ligand in preventing graft rejection

D. Bellgrau, D. Gold, Jodene K Moore, 1995, Nature.

A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance

A. Bertoletti, D. Bellgrau, A. Gaggar, 2014, PloS one.

The cytokine storm – An appropriate, over‐reactive response to SARS‐COV‐2 or the wrong immune pathway?

J. Modiano, D. Bellgrau, 2020, Scandinavian journal of immunology.

Prevention of Diabetes in Rats by Bone Marrow Transplantation

W. Silvers, D. Bellgrau, S. Plotkin, 1981, Annals of surgery.

Resistance to tolerance induction in the diabetes-prone Biobreeding rat as one manifestation of abnormal responses to superantigens

D. Bellgrau, D. Gold, K. Sellins, 1996, Diabetologia.

A diabetogenic gene prevents T cells from receiving costimulatory signals.

Å. Lernmark, S. Dreskin, J. K. Moore, 1999, Cellular immunology.

T cells from BB-DP rats show a unique cytokine mRNA profile associated with the IDDM1 susceptibility gene, Lyp.

Å. Lernmark, D. Bellgrau, D. Gold, 1995, Autoimmunity.

Proinflammatory consequences of transgenic fas ligand expression in the heart.

D. Nelson, S. Schwartz, D. Bellgrau, 2000, The Journal of clinical investigation.

Enhancing antimelanoma immune responses through apoptosis

G. Cutter, S. Fosmire, J. Modiano, 2003, Cancer Gene Therapy.

Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis

J. Modiano, D. Bellgrau, M. G. O’Sullivan, 2014, PloS one.

Peculiar T-Cell Signaling Does Not Preclude Positive Selection in the Diabetes-Prone BB Rat

D. Bellgrau, K. Sellins, J. Redd, 1994, Diabetes.

Loss of a gimap/ian gene leads to activation of NF-kappaB through a MAPK-dependent pathway.

D. Bellgrau, R. Scheinman, J. Lang, 2007, Molecular immunology.

Islet Allografts Are Destroyed by Disease Occurrence in the Spontaneously Diabetic BB Rat

D. Bellgrau, K. Lafferty, S. Prowse, 1986, Diabetes.

T cell dysfunction in the diabetes-prone BB rat. A role for thymic migrants that are not T cell precursors

D. Bellgrau, H. Georgiou, A. Lagarde, 1988, The Journal of experimental medicine.

Thymus transplantation and disease prevention in the diabetes-prone Bio-Breeding rat.

D. Bellgrau, H. Georgiou, 1989, Journal of immunology.

Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire.

D. Bellgrau, A. Lagarde, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

D. Kuritzkes, D. Bellgrau, Cara C Wilson, 2001, Nature Medicine.

Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma

D. Bellgrau, K. Lillehei, B. Kleinschmidt-DeMasters, 1993, Journal of Neuro-Oncology.

Nicotine Activates Nuclear Factor of Activated T Cells c2 (NFATc2) and Prevents Cell Cycle Entry in T Cells

S. Baksh, S. Fosmire, J. Modiano, 2004, Journal of Pharmacology and Experimental Therapeutics.

Analytical and functional studies on the T cells of untreated and immunologically tolerant diabetes-prone BB rats.

W. Silvers, J. Markmann, D. Bellgrau, 1983, Journal of immunology.

IL-6-inducing Whole Yeast-based Immunotherapy Directly Controls IL-12-dependent CD8 T-cell Responses

D. Bellgrau, R. Kedl, B. Tamburini, 2012, Journal of immunotherapy.

Diabetogenic Activation State Controlled by a The Identification of a Novel T Cell

J. K. Moore, D. Bellgrau, R. Scheinman, 2000 .

Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene

F. Graham, D. Bellgrau, J. Routes, 1991, Journal of virology.

Abdominal Intratesticular Islet-Xenograft Survival in Rats

D. Bellgrau, K. Whittington, H. Selawry, 1989, Diabetes.

A Mediator of Cytotoxic T Lymphocyte-Mediated Apoptosis and Immune Privilege

E. Newell, D. Bellgrau, Jodene K Moore, 1997 .

CD95 (Fas) Ligand

E. Newell, D. Bellgrau, Jodene K Moore, 1997 .

CD95 ligand in graft rejection

D. Bellgrau, A. Franzusoff, R. C. Duke, 1996, Nature.

Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.

J. Modiano, D. Bellgrau, R. Gianani, 2004, Clinical immunology.

Transplantation of cells and tissues expressing Fas ligand.

E. Newell, D. Bellgrau, S. Meech, 1999, Transplantation proceedings.

Murine heart transgenic Fas ligand expression protects against allograft rejection.

D. Nelson, D. Bellgrau, E. Setser, 2002, Transplantation proceedings.

Apoptosis and CD95 ligand in immune privileged sites.

D. Bellgrau, R. C. Duke, 1999, International reviews of immunology.

Spontaneous diabetes in BB rats: Evidence for a T cell dependent immune response defect

W. Silvers, J. Markmann, D. Bellgrau, 1982, Diabetologia.

Natural Killer Cells Do Not Belong to the Recirculating Lymphocyte Population

M. Zöller, D. Bellgrau, H. Wigzell, 1982, Scandinavian journal of immunology.

Specificity of rat T cell receptor Vβ chain usage in proliferative responses to staphylococcal enterotoxin B

D. Bellgrau, D. Gold, K. Sellins, 1992 .

Specific systemic graft-versus-host resistance: failure to induce in adult F1 rats tolerized at birth to anti-MHC receptors on parental T cells.

D. Wilson, D. Bellgrau, D. Smilek, 1982, Advances in experimental medicine and biology.

Immunological studies of T-cell receptors. II. Limited polymorphism of idiotypic determinants on T-cell receptors specific for major histocompatibility complex alloantigens

D. Wilson, D. Bellgrau, 1979, The Journal of experimental medicine.

Allogeneic tumor-specific cytotoxic T lymphocytes

D. Bellgrau, C. Kruse, J. Redd, 2005, Cancer Immunology, Immunotherapy.

A 9L Gliosarcoma Transplantation Model for Studying Adoptive Immunotherapy into the Brains of Conscious Rats

L. Watkins, M. Fleshner, D. Bellgrau, 1992, Cell transplantation.

A requirement for the CD5 antigen in T cell activation

D. Bellgrau, H. Georgiou, A. Lagarde, 1988, European journal of immunology.

Complex formation of class I transplantation antigens and a viral glycoprotein.

P. A. Peterson, S. Pääbo, D. Bellgrau, 1983, The Journal of biological chemistry.

Identification of a limited T-cell receptor beta chain variable region repertoire associated with diabetes in the BB rat.

D. Bellgrau, D. Gold, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors

D. Bellgrau, B. Kleinschmidt-DeMasters, C. Kruse, 2005, Journal of Neuro-Oncology.

Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

D. Bellgrau, K. Lillehei, B. Kleinschmidt-DeMasters, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Studies on the two-signal model for T cell activation in vivo.

D. Bellgrau, K. Lafferty, R. Gill, 1987, Transplantation proceedings.

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma

G. Cutter, T. Phang, L. Hunter, 2010, BMC Cancer.

CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma

S. Fosmire, J. Modiano, D. Bellgrau, 2005, Veterinary pathology.

Immunological studies of T-cell receptors. I. Specifically induced resistance to graft-versus-host disease in rats mediated by host T-cell immunity to alloreactive parental T cells

D. Wilson, D. Bellgrau, 1978, The Journal of experimental medicine.

Spontaneous diabetes in rats: destruction of islets is prevented by immunological tolerance.

W. Silvers, D. Bellgrau, A. Naji, 1981, Science.

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis

S. Furney, I. Orme, D. Bellgrau, 2017, Clinical and Vaccine Immunology.

Transplantation of Islets and Bone Marrow Cells to Animals with Immune Insulitis

W. Silvers, D. Bellgrau, A. Naji, 1982, Diabetes.

Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy

L. Dwyer-Nield, A. Malkinson, D. Bellgrau, 2004, Cancer Research.

Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer.

G. Cutter, V. Wilke, J. Modiano, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Naturally occurring translational models for development of cancer gene therapy

S. Fosmire, J. Modiano, D. Bellgrau, 2006 .

Induction of cytotoxic T cell precursors in vivo. Role of T helper cells

D. Bellgrau, 1983, The Journal of experimental medicine.

Negative regulators in homeostasis of naïve peripheral T cells

J. Modiano, D. Bellgrau, L. D. Johnson, 2008, Immunologic research.

Cell surface energy and membrane associated actin in lymphocytes

D. Bellgrau, D. Gerson, B. Mély-Goubert, 1988, Cell Biophysics.

Recognition of adenovirus E1A gene products on immortalized cell surfaces by cytotoxic T lymphocytes

D. Bellgrau, T. Walker, J. Cook, 1988, Journal of virology.

Specific changes in lymphocyte subpopulations: a potential mechanism for stress-induced immunomodulation

S. Maier, L. Watkins, M. Laudenslager, 1992, Journal of Neuroimmunology.

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

G. Lauer, D. Bellgrau, A. A. Haller, 2007, Vaccine.

FAS ligand gene transfer for cancer therapy

J. Modiano, D. Bellgrau, J. Schaack, 2005 .

Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth?

J. Modiano, D. Bellgrau, 2016, Discovery medicine.

The Identification of a Novel T Cell Activation State Controlled by a Diabetogenic Gene1

D. Bellgrau, R. Scheinman, Jodene K Moore, 2001, The Journal of Immunology.

Induced tolerance in F1 rats to anti-major histocompatibility complex receptors on parental T cells. Implications for self tolerance

D. Wilson, D. Bellgrau, D. Smilek, 1981, The Journal of experimental medicine.

Stress-induced reduction in the rat mixed lymphocyte reaction is due to macrophages and not to changes in T cell phenotypes

S. Maier, L. Watkins, M. Laudenslager, 1995, Journal of Neuroimmunology.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

D. Bellgrau, M. Morse, B. O'Neil, 2018, Journal of immunotherapy.

MHC-dependent desensitization of intrinsic anti-self reactivity

G. Cutter, M. Baier, J. Modiano, 2009, Cancer Immunology, Immunotherapy.

T Cell Mediated Immune Response to Anti-MHC Receptors

D. Bellgrau, Darcy B. Wilson, D. Smilek, 1980 .

Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment

J. Tolar, J. Modiano, C. Forster, 2015, Cancer Immunology, Immunotherapy.

Cyclosporine-induced tolerance to intratesticular islet xenografts.

D. Bellgrau, H. Selawry, 1990, Transplantation.

E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes.

T. Potter, D. Bellgrau, B. A. Routes, 1996, Oncogene.

Actin content in lymphocytes: a proposed correlation with their recirculating properties.

D. Bellgrau, B. Mély-Goubert, 1981, Journal of immunology.

Yeast-based immunotherapy and the threshold of EGFR expression for immune recognition against glioma overexpressing self-antigen

D. Bellgrau, A. Franzusoff, T. Rodell, 2006 .

Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial

D. Bellgrau, M. Morse, S. Munson, 2005 .

Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer.

D. Bellgrau, J. Schaack, S. Munson, 2011, Molecular Therapy.

The Diabetic BB Rat Neither Th1 nor Th2?

D. Bellgrau, D. Stenger, C. Richards, 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.